Discovery of a novel inhibitor of macropinocytosis with antiviral activityShow others and affiliations
2024 (English)In: Molecular Therapy, ISSN 1525-0016, E-ISSN 1525-0024, Vol. 32, no 9, p. 3012-3024Article in journal (Refereed) Published
Abstract [en]
Several viruses hijack various forms of endocytosis in order to infect host cells. Here, we report the discovery of a molecule with antiviral properties that we named virapinib, which limits viral entry by macropinocytosis. The identification of virapinib derives from a chemical screen using high-throughput microscopy, where we identified chemical entities capable of preventing infection with a pseudotype virus expressing the spike (S) protein from SARS-CoV-2. Subsequent experiments confirmed the capacity of virapinib to inhibit infection by SARS-CoV-2, as well as by additional viruses, such as mpox virus and TBEV. Mechanistic analyses revealed that the compound inhibited macropinocytosis, limiting this entry route for the viruses. Importantly, virapinib has no significant toxicity to host cells. In summary, we present the discovery of a molecule that inhibits macropinocytosis, thereby limiting the infectivity of viruses that use this entry route such as SARS-CoV2.
Place, publisher, year, edition, pages
CELL PRESS , 2024. Vol. 32, no 9, p. 3012-3024
National Category
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Identifiers
URN: urn:nbn:se:liu:diva-207976DOI: 10.1016/j.ymthe.2024.06.038ISI: 001318535900001PubMedID: 38956870OAI: oai:DiVA.org:liu-207976DiVA, id: diva2:1903180
Note
Funding Agencies|Chemical Biology Consortium Sweden (CBCS) , node Uppsala university - Swedish Research Council [dr.nr.2021-00179]; SciLifeLab - Cancerfonden foundation [CAN 21/1529]; Swedish Research Council [2019-01837, 2021-02801]; EU/EFPIA/OICR/McGill/KTH/Diamond Inno-vative Medicines Initiative 2 Joint Undertaking [875510, 2020-02682]; Human Frontier Science Program [RGP0025/2022]; Marie Sklstrok;odowska-Curie Actions Postdoctoral Fellowship [101059180]
2024-10-032024-10-032025-04-23